Glucagon antagonists

US8907103B2 · kind B2 · utility

Assignee

• Metabasis Therapeutics, Inc. · US

Inventors

• Jorge E. Gomez-Galeno · San Diego, US
• Scott Hecker · Del Mar, US
• Qun Dang · Westfield, US
• Mali Venkat Reddy · San Diego, US
• Zhili Sun · San Diego, US
• Matthew P. Grote · Carlsbad, US
• Thanh Huu Nguyen · Solana Beach, US
• Robert Huerta Lemus · Escondido, US
• Haiqing Li · San Diego, US

Key dates

• Filing date: Aug 13, 2009
• Grant date: Dec 9, 2014
• Expiry date: Jan 2, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof. Formula I